SLC5A1 and hydrops fetalis: This randomized controlled trial demonstrated that sotagliflozin, a dual SGLT1 and 2 inhibitor, led to a significant decrease in the primary endpoint of cardiovascular death, hospitalizations for HF, and urgent visits for HF (HR 0.67, p < 0.001) when administered either at the time of patient discharge or within 3 days following discharge [11].